Granted Patent B2

US 12,746,201 · App. 18/673,962 · Granted Sep 29, 2026

Inventors: Neeraj Narendra Patwardhan (Cambridge, MA); Milloni Balwantkumar Chhabra (Cambridge, MA); Gregory Lawrence Hamilton (Cambridge, MA); Cory Dane Sago (Cambridge, MA); Mina Fawzy Gaballa Shehata (Cambridge, MA)

Assignee: Guide Therapeutics, LLC

A61K9/1272A61K9/1277C12N15/113

Abstract

Claims (32)

1 . A compound of Formula (IIb):

wherein:

R 9 is C 9 -C 20 alkyl optionally fused with 1-4 C 3 -C 6 cycloalkyl groups, C 9 -C 20 alkenyl with 1-3 units of unsaturation, or —(CH 2 ) g —X 17 , wherein X 17 is optionally substituted C 4 -C 12 cycloalkyl;

f is independently an integer from 0-6;

R 16 is hydrogen or optionally substituted C 5 -C 6 aryl;

X 15 is optionally substituted C 4 -C 12 cycloalkyl or optionally substituted C 5 -C 10 aryl; and

X 16 is hydrogen or optionally substituted C 4 -C 12 cycloalkyl;

provided that when f is 1 and R 9 is

 X 15 is not

2 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

3 . The compound of claim 2 , having the following structure

4 . The compound of claim 2 , having the following structure

5 . The compound of claim 2 , having the following structure

6 . The compound of claim 2 , having the following structure

7 . The compound of claim 2 , having the following structure

8 . The compound of claim 2 , having the following structure

9 . The compound of claim 2 , having the following structure

10 . The compound of claim 2 , having the following structure

11 . The compound of claim 2 , having the following structure

12 . A lipid nanoparticle composition comprising:

an ionizable lipid that is the compound of claim 1 ;

a phospholipid;

a polyethylene glycol-lipid; and

a cholesterol.

13 . The lipid nanoparticle composition of claim 1 , further comprising a nucleic acid.

14 . The lipid nanoparticle composition of claim 12 , wherein the amount of ionizable lipid is present in the range of about 35 to 65 mole percent, based on total moles.

15 . The lipid nanoparticle composition of claim 12 , wherein the phospholipid is DSPC.

16 . The lipid nanoparticle composition of claim 12 , wherein the phospholipid is DMPC.

17 . A method of delivering a nucleic acid to a subject in need thereof, comprising administering to the subject the lipid nanoparticle composition of claim 12 .

18 . The lipid nanoparticle composition of claim 13 , wherein the nucleic acid is siRNA, miRNA, anti-sense oligonucleotide, or immunostimulatory oligonucleotide.

19 . The lipid nanoparticle composition of claim 12 , wherein the polyethylene glycol-lipid is DMG-PEG2000.

20 . The lipid nanoparticle composition of claim 12 , wherein the polyethylene glycol-lipid is DSG-PEG2000.

Assignments (5)

Continuity (3)

References Cited (157)